Concurrent paclitaxel and radiation therapy for solid tumors

H. Choy, W. Akerley, M. Glantz, H. Safran, S. Graziano, C. Chung

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalCancer Control
Issue number4
StatePublished - 1996

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


Dive into the research topics of 'Concurrent paclitaxel and radiation therapy for solid tumors'. Together they form a unique fingerprint.

Cite this